The involvement of differential expression of miR-193b-3p in the development of cardiovascular complications of T2DM and in the implementation of the protective effect of SGLT2 inhibitors seems promising for further investigation. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.